logo

Regional Content Customized for the United Kingdom (UK)

This section contains resources customized for the UK healthcare professional.

New! Stage IV Decision-Support Tool

Welcome to this guide, Stage IV Melanoma Treatment Options: Making the Decision That’s Right for You. You can use this guide to discuss therapeutic options for managing Stage IV melanoma with your patients.

The document addresses

  • Stage IV melanoma clinical picture, biomarkers and pathology, and disease and patient factors involved in decision making
  • Efficacy, safety, administration, and family-planning aspects of targeted therapies, immune checkpoint inhibitors, and other therapies used for stage IV melanoma
  • Management of brain metastases, including radiation therapy
  • Clinical trials, including an overview of emerging therapies being studied
  • Survivorship and advanced care planning
  • Diagnosis (including biopsy techniques) as well as an overview of imaging
  • Practical patient resources

Developed in collaboration with Melanoma UK.

Download Now

COVID-19 Vaccine Recommendations for IO Patients

In the following videos, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, discusses the use of COVID-19 vaccines in patients with cancer, particularly in those receiving immune checkpoint inhibitors (ICIs). The content is customised to the UK region. This content was recorded on  July 7, 2021 and reflects the status of vaccine approvals as of that date. For an updated list of the currently available vaccines approved in the UK, please click here: https://covid19.trackvaccines.org/country/united-kingdom-of-great-britain-and-northern-ireland/

 

Review of available COVID-19 vaccines

 

Timing of receipt of vaccines (in general and with haematopoietic cell transplantation and CAR T-cell therapies)

 

COVID-19 vaccines and ICIs (sequencing, monitoring, and side effects)

 

Addressing frequently asked questions and myths about COVID-19 vaccines

 

What to watch for in the future—new COVID-19 vaccine options, impact of variants, and the need for boosters

Stage III Decision-Support Materials

Updated Stage III Decision Support Tool

The Decision-Support Tool has been updated with information you need to know about outcomes for Stage III melanoma, long-term data for adjuvant therapies, and additional resources, including content specific for caregivers.

Developed in collaboration with the Melanoma UK.

Click Here to Download

New Stage III Companion Piece

Want to learn how to use the Stage III Decision-Support Tool? Peruse frequently asked questions about Stage III melanoma and learn how to use the support tool to guide your decision making.

Developed in collaboration with the Melanoma UK.

Click Here to Download

Optimising Care During the COVID-19 Pandemic

In the series of videos below, Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, shares perspectives and tips for optimising care during these challenging times.

Optimising Telemedicine

Use of Extended Dosing Intervals for Immunotherapy

Changes in Infusion Practices

Minimising the Impact on Clinical Trials

Care Step Pathways

This section provides stand-alone Care Step Pathways (CSPs) that have been customized for the UK audience. We wish to thank Emmanouil Nikolousis, FRCP, FRCPath, PhD, MBA, Consultant Haematologist at University Hospitals Birmingham, for thoughtful review of these materials.

List of CSPs

For Immunotherapy (Checkpoint Inhibitors):
Ipilimumab
Nivolumab
Pembrolizumab
Nivolumab/Ipilimumab

For Intralesional Therapy:
Talimogene laherparepvec; T-VEC

Patient Resources

Action Plans

This section contains the customizable action plans for patients with different tumor types that have been customized for the UK audience. We wish to thank Kris Griffin, patient advocate, for his helpful review of these materials.

Talimogene laherparepvec; T-VEC

Pembrolizumab

Nivolumab

Nivolumab/Ipilimumab

Ipilimumab

© 2022 AIM with Immunotherapy. All rights reserved.